Reliance Global Group (EZRA) investor relations material

Executive summary

• Focused on simplifying operations, strengthening the balance sheet, and establishing a framework for long-term growth, with an active execution phase and expansion into technology and life sciences through Scale51 and LifeSci Global Group.

• Operates two segments: insurance/InsurTech platform for recurring revenue and strategic ventures (EZRA International, Scale51) for disciplined capital deployment in tech and life sciences.

• Enhanced RELI Exchange platform and expanded direct-to-consumer reach with 5MinuteInsure.com, supporting organic growth and operational efficiency.

• Strategic investments in post-quantum cybersecurity (Enquantum) and life sciences (LifeSci Global, Innervate Radiopharmaceuticals) using milestone-based, phased capital deployment.

• Insurance platform provides stable cash flow, enabling selective investment in high-growth opportunities.

Financial highlights

• Unrestricted cash increased to $2.3M from $1.3M sequentially; combined cash rose to $3.2M from $2.7M.

• Working capital improved to $2.6M from $1.9M; stockholders' equity increased to $7.4M from $6.4M.

• Commission income was $3.8M, down from $4.2M year-over-year due to divestitures, but retained businesses saw 11% organic revenue growth.

• Net loss improved to $1.4M from $1.7M year-over-year, driven by lower operating and interest expenses.

• Adjusted EBITDA was -$0.4M versus +$0.1M year-over-year, reflecting lower stock-based compensation add-backs.

Outlook and guidance

• Plans to continue disciplined execution of the dual-segment model, broadening investment opportunities and advancing current holdings.

• Expects further organic growth in insurance through technology enhancements and agent expansion.

• Strategic ventures will focus on milestone-based capital deployment and selective acquisitions in tech and life sciences.

• Management believes current liquidity and capital resources are sufficient for at least the next twelve months.

• Reverse stock split aims to regain Nasdaq compliance; no assurance of sustained compliance.